Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)
Benitec Biopharma (BNTC) posted Net Income towards Common Stockholders of -$11.8 million for Q4 2025, down 32.04% sequentially from -$9.0 million in Q3 2025, and down 23.92% YoY from -$15.6 million in Q4 2024.
Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$11.8 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 23.92% year-over-year to -$11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$44.1 million (down 86.82% YoY) and the FY2025 annual result came in at -$37.9 million, down 69.5% from the prior year.
- Net Income towards Common Stockholders fell to -$11.8 million in Q4 2025 per BNTC's latest filing, from -$9.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$3.6 million in Q1 2022 and troughed at -$16.4 million in Q2 2023.
- A 5-year average of -$7.1 million and a median of -$5.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2025: Net Income towards Common Stockholders soared 74.98% in 2021, then slumped 238.89% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$5.0 million in 2021, then fell by 27.07% to -$6.3 million in 2022, then decreased by 7.27% to -$6.8 million in 2023, then slumped by 40.51% to -$9.6 million in 2024, then dropped by 23.92% to -$11.8 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$11.8 million, -$9.0 million, and -$8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | -11.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.84 Mn |
| Sep 30, 2025 | -8.97 Mn |
| Jun 30, 2025 | -8.81 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Sep 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -4.72 Mn |
| Mar 31, 2024 | -4.28 Mn |
| Dec 31, 2023 | -6.80 Mn |
| Sep 30, 2023 | -6.57 Mn |
| Jun 30, 2023 | -16.44 Mn |
| Mar 31, 2023 | -5.84 Mn |
| Dec 31, 2022 | -6.34 Mn |
| Sep 30, 2022 | -5.38 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.99 Mn |
| Sep 30, 2021 | -5.05 Mn |
| Jun 30, 2021 | -4.05 Mn |
| Mar 31, 2021 | -3.80 Mn |